These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 23795352)

  • 1. [Prognostic and predictive markers of malignant melanoma].
    Rásó E; Barbai T; Gyõrffy B; Tímár J
    Magy Onkol; 2013 Jun; 57(2):79-83. PubMed ID: 23795352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecularly targeted therapies for melanoma.
    Liu LS; Colegio OR
    Int J Dermatol; 2013 May; 52(5):523-30. PubMed ID: 23590367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenetics of melanoma: basis for molecular diagnostics and therapy.
    Held L; Eigentler TK; Meier F; Held M; Röcken M; Garbe C; Bauer J
    J Dtsch Dermatol Ges; 2011 Jul; 9(7):510-6. PubMed ID: 21244632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Genetic diversity and immunological characteristics of malignant melanoma: the therapeutic spectrum].
    Doma V; Gulya E
    Orv Hetil; 2015 Apr; 156(15):583-91. PubMed ID: 25845317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Melanoma and search for therapeutic targets].
    de la Fouchardière A
    Ann Pathol; 2011 Nov; 31(5 Suppl):S123-4. PubMed ID: 22054449
    [No Abstract]   [Full Text] [Related]  

  • 6. Mutation stability in primary and metastatic melanoma: what we know and what we don't.
    Varada S; Mahalingam M
    Histol Histopathol; 2015 Jul; 30(7):763-70. PubMed ID: 25585249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy resistance mechanisms and therapeutic implications in melanoma.
    Chen G; Davies MA
    Hematol Oncol Clin North Am; 2014 Jun; 28(3):523-36. PubMed ID: 24880945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].
    Capovilla M
    Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers in melanoma.
    Griewank KG
    Scand J Clin Lab Invest Suppl; 2016; 245():S104-12. PubMed ID: 27467728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapidly metastasizing malignant melanoma characterized by a rare BRAF mutation not responding to vemurafenib.
    Starz H; Gutschi M; Welzel J; Haas C
    J Dtsch Dermatol Ges; 2014 Feb; 12(2):151-4. PubMed ID: 24238398
    [No Abstract]   [Full Text] [Related]  

  • 11. Undifferentiated Sarcoma as Intermediate Step in Rhabdomyosarcomatous Transformation of a Metastatic Malignant Melanoma Resistant to Anti-BRAF Therapy: A Phenomenon Associated With Significant Diagnostic and Therapeutic Pitfalls.
    Tran TAN
    Int J Surg Pathol; 2019 Sep; 27(6):669-677. PubMed ID: 30942107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations.
    Bradish JR; Montironi R; Lopez-Beltran A; Post KM; MacLennan GT; Cheng L
    Future Oncol; 2013 Feb; 9(2):245-53. PubMed ID: 23414474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Targeted therapy of melanoma: fact or fiction?].
    Svajdler M; Rychlý B; Benický M
    Cesk Patol; 2011 Oct; 47(4):165-7. PubMed ID: 22145215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
    Yaman B; Akalin T; Kandiloğlu G
    Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Gene abnormalities in melanoma and signal transduction antagonists].
    Takada M
    Gan To Kagaku Ryoho; 2013 Apr; 40(4):453-7. PubMed ID: 23894754
    [No Abstract]   [Full Text] [Related]  

  • 16. The molecular profile of metastatic melanoma in Australia.
    Lyle M; Haydu LE; Menzies AM; Thompson JF; Saw RP; Spillane AJ; Kefford RF; Mann GJ; Cooper WA; Yu B; Scolyer RA; O'Toole SA; Long GV
    Pathology; 2016 Feb; 48(2):188-93. PubMed ID: 27020391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new standard of care for metastatic melanoma?
    Sharma SP
    Lancet Oncol; 2015 Jan; 16(1):e8. PubMed ID: 25638559
    [No Abstract]   [Full Text] [Related]  

  • 18. Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights.
    Dummer R; Flaherty KT
    Curr Opin Oncol; 2012 Mar; 24(2):150-4. PubMed ID: 22316627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Melanoma: from molecular studies to the treatment breakthrough].
    Imianitov EN
    Arkh Patol; 2013; 75(5):63-72. PubMed ID: 24341237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
    Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
    J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.